SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-14-172052
Filing Date
2014-04-30
Accepted
2014-04-30 16:10:10
Documents
6
Period of Report
2014-06-27
Effectiveness Date
2014-04-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A d711452ddef14a.htm DEF 14A 585529
2 GRAPHIC g711452g01a01.jpg GRAPHIC 134409
3 GRAPHIC g711452g01a02.jpg GRAPHIC 122163
4 GRAPHIC g711452g07o65.jpg GRAPHIC 12466
5 GRAPHIC g711452g34q38.jpg GRAPHIC 8317
6 GRAPHIC g711452g80i40.jpg GRAPHIC 6878
  Complete submission text file 0001193125-14-172052.txt   978954
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Filer) CIK: 0001382911 (see all company filings)

IRS No.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33415 | Film No.: 14798801
SIC: 2834 Pharmaceutical Preparations